Drug Information

Drug (ID: DG00489) and It's Reported Resistant Information

• Name: HER2 inhibitors
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Breast cancer [ICD-11: 2C60]; [1], [2]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Breast cancer [ICD-11: 2C60]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: PI3-kinase alpha (PIK3CA) [1], [2]

• Molecule Alteration: Mutation; .
• Resistant Disease: Breast cancer [ICD-11: 2C60.3]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: AKT signaling pathway; Activation; hsa04151
• In Vivo Model: A retrospective survey in conducting clinical studies; Homo sapiens
• Experiment for Molecule Alteration: Qubit HS dsDNA assay; Illumina sequencing assay; Sanger sequencing assay
• Mechanism Description: PIk3CA mutations may have independent driver properties in a HER2+ context and have been implicated in resistance to anti-HER2 therapies.

References

• Ref 1: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):215. doi: 10.1186/bcr1612.
• Ref 2: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479.